$CLOV

OLDAKOWSKI JOSEPH FRANK sold $15K of CLOV

OLDAKOWSKI JOSEPH FRANK (VP OF FINANCE AND CONTROLLER) sold 3,170 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.64 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · OLDAKOWSKI JOSEPH FRANK
Published Sep 17, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to affect market perception of Clover Health.

02

Market read

A small insider sell with no immediate price impact; primarily of interest to compliance and monitoring teams.

03

What to watch

Potential future dilution from upcoming financing rounds could make the current stake less significant.

Relevance 2/10Novelty 3/10Timing: post‑market 2026‑09‑16 filing

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑scheduled trades.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

VP of Finance sold 3,170 shares for $14.7K via a 10b5‑1 plan, reducing his stake to 275,897 shares.

Expected impact

No material price impact expected.

Evidence & confidence

The sale size is small relative to float and disclosed under a pre‑arranged plan, indicating routine portfolio rebalancing rather than loss of confidence.

Market effects

None; the transaction is company‑specific and does not affect the health‑tech sector.

None; Clover Health trades on US exchanges only.

None; the sale is too small to influence broader markets.

Counterpoint

If the insider had insider knowledge of upcoming negative news, the sale could be a warning sign, but the 10b5‑1 plan weakens that argument.

Key entities

  • Clover Health Investments, Corp.

    US‑listed health‑tech firm (ticker CLOV).

  • Joseph Frank Oldakowski

    Vice President of Finance and Controller, insider reporter.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLOVHigh

Why is Clover Health stock climbing 4% today?

Clover Health (CLOV) stock rose 4.3% in pre-market trading after Needham initiated coverage with a Buy rating and $6.00 price target, citing its Medicare Advantage rating and cohort economics. The company's upcoming conference presentation and Q3 earnings report also contributed to the positive sentiment. The Nasdaq Composite was up 0.5% in pre-market.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$CLOVHigh

Why Is Clover Health (CLOV) Stock Soaring Today

Clover Health (CLOV) stock rose 10.7% premarket after CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The ratings, excluding disputed measures, boost payments and enrollment. Shares later cooled to $4.81, up 5%. CLOV is up 99.5% YTD but still below its 52-week high.

$CLOVMed

Is Clover Health Stock Too Dependent On One Group Of Members?

Clover Health Investments (CLOV) reported that nearly half of its Medicare Advantage members joined in 2025 or 2026, impacting short-term profits. Membership grew 48% YoY to 157,000, with new members accounting for 49%. Despite a 70% stock return over 12 months, CLOV's revenue declined 0.7%, and gross profit grew slower than revenue. Management raised full-year guidance but cautioned about future trends.

$CLOVMed

Clover Health Medicare Advantage PPO Plans Earn 5-Star Rating; HMO at 4.5 Stars

Clover Health's PPO Medicare Advantage plans received a 5.0 Star rating and HMO plans 4.5 Stars for 2027, impacting 2028 payments. CMS removed 20 measures for PPO plans, raising their rating. Clover's MA membership grew ~48% YoY to >157,000 members, with 98% in PPO plans. The company ranked #1 among non-SNP PPO plans with >2,000 members on core HEDIS measures, scoring 4.82 out of 5.